TICKERNERD
Menu
GLUEGLUEHealthcare · Biotechnology

GLUE Stock Forecast: Monte Rosa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$10
+1.47% on the day

The 9 Wall Street analysts covering Monte Rosa Therapeutics, Inc. hold a median 12-month price target of $27 — +161.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 63 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$880.4M
Ticker Nerd rank
63 / 100
Median analyst target
$27
Analysts covering
9
Revenue$9.0M−61.3% y/y
Operating income−$49.1M
Net income−$43.4M
Free cash flow−$48.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.3%
1M
−27.7%
YTD
−34.2%
1Y
+33.9%
From 52W high
−59.2%
From 52W low
+33.9%
$8
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GLUE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Monte Rosa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
63 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
82
Quality
77
Momentum
71
Revisions
70
Value
57
Size
46
Issuance
41
Volatility
30
Growth
17

Accruals (82): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GLUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GLUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26GLUEHigh $37Median $27Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $25Median $27High $37

The green dot is the last close — the median target sits +161.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$25
1 Oct 2026HC Wainwright & Co.InitiatesBuy$25
9 Sept 2026WedbushReiteratesOutperform—
9 Sept 2026WedbushReiteratesOutperform$27
25 Aug 2026GuggenheimReiteratesBuy$28
25 Aug 2026GuggenheimReiteratesBuy—
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026GuggenheimMaintainsBuy$35 → $28
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026JP MorganMaintainsOverweight$31 → $27
7 Aug 2026Wells FargoMaintainsOverweight$29 → $27
7 Aug 2026Wells FargoMaintainsOverweight—
3 Aug 2026WedbushMaintainsOutperform$37 → $27
3 Aug 2026WedbushMaintainsOutperform—
30 June 2026GuggenheimMaintainsBuy—
30 June 2026GuggenheimMaintainsBuy$30 → $35
11 May 2026JP MorganMaintainsOverweight—
18 Mar 2026GuggenheimMaintainsBuy—
18 Mar 2026Wells FargoMaintainsOverweight—
14 Jan 2026Piper SandlerReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GLUE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

GLUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Monte Rosa Therapeutics, Inc. returned +33.9% against +16.2% for the S&P 500, dividends included.

GLUE vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26GLUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GLUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
1
Fundamentals

Monte Rosa Therapeutics, Inc. (GLUE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
49.2×

Cheaper than 15% of US stocks

Price / sales
30.6×

Cheaper than 7% of US stocks

Price / book
1.8×

Cheaper than 48% of US stocks

EV / EBITDA
−1.6×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−61.3%

Higher than 4% of US stocks

Earnings growth (YoY)
−61.3%

Higher than 8% of US stocks

Gross margin
—
Operating margin
−547.8%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−42.7%

Higher than 24% of US stocks

Return on assets
−21.6%

Higher than 18% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Monte Rosa Therapeutics, Inc. (GLUE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Monte Rosa Therapeutics, Inc. has a market value of $880.4M and an enterprise value of $284.5M.

  • Revenue in the twelve months to 30 June 2026: $28.7M. The latest quarter shrank 61.3% year on year.

  • Net income over the same four quarters: −$161.1M, a −560.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.18.

  • Free cash flow in the twelve months to 30 June 2026: −$32.1M.

  • Shares outstanding: 85.2M.

  • Trailing P/E: 49.2×; forward P/E: −5.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Monte Rosa Therapeutics, Inc. employs 173 people — $166K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

GLUE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GLUEMonte Rosa Therapeutics, Inc.$880.4M
63
TBPHTheravance Biopharma, Inc.$857.7M
—
ALMSAlumis, Inc.$886.6M
42
CRVSCorvus Pharmaceuticals, Inc.$855.3M
54
ODTXOdyssey Therapeutics, Inc.$854.8M
1
SLBTSL Science Holding Ltd.$852.4M
1
JBIOJade Biosciences, Inc.$899.9M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Monte Rosa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GLUE news & analysis

Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study

MarketBeat · 6 Oct 2026positive

Monte Rosa Therapeutics reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The four-week dosing study showed sustained NEK7 degradation, reductions in inflammatory and atherogenic biomarkers, and a safety profile comparable with placebo.

Why it matters — The results suggest MRT-8102 is hitting its biological targets with an encouraging safety profile, marking a meaningful clinical milestone for the company's lead pipeline candidate.

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 2 Oct 2026neutral

Monte Rosa Therapeutics granted inducement equity awards to five newly hired non-executive employees, including non-qualified stock options to purchase 86,725 shares at an exercise price of $11.26 and restricted stock units covering 19,150 shares, both subject to performance-based vesting schedules tied to continued employment.

Why it matters — GLUE watchers would care because the inducement grants signal hiring and incentive activity in the company's workforce, offered under Nasdaq Rule 5635(c)(4).

Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk Transcript

Seeking Alpha · 1 Oct 2026neutral

Monte Rosa Therapeutics discussed results from its GFORCE-1 Phase I trial of MRT-8102, a NEK7 molecular glue degrader being studied in cardiovascular disease risk, in a transcript published on Seeking Alpha. The item covers the company's presentation of these Phase I data for the candidate.

Why it matters — These Phase I results provide an early read on MRT-8102, a key pipeline candidate targeting cardiovascular disease risk, and offer GLUE watchers insight into the program's clinical progress.

Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease

Benzinga · 1 Oct 2026positive

Monte Rosa Therapeutics reported Phase 1 trial results for its inflammatory disease drug candidate MRT-8102, and outlined plans to advance the treatment into multiple Phase 2 studies. The drug candidate shows potential for cardiovascular disease.

Why it matters — A GLUE watcher would care because progression of MRT-8102 into Phase 2 studies marks a key pipeline milestone for the company's inflammatory and cardiovascular disease program.

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

GlobeNewsWire · 1 Oct 2026positive

Monte Rosa Therapeutics reported positive results from the GFORCE-1 Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader, in obese subjects at elevated cardiovascular disease risk. The drug normalized multiple key pathogenic drivers of atherosclerotic cardiovascular disease, showed robust NEK7 degradation across three dose levels, and was safe and well tolerated over four weeks of dosing and follow-up, with Phase 2 trials planned in coronary artery disease, gout, and hidradenitis suppurativa.

Why it matters — The positive Phase 1 data validate MRT-8102's mechanism and support advancing the drug into Phase 2 trials across multiple indications, marking a significant clinical development milestone for Monte Rosa's pipeline.

FAQ

Frequently asked questions about GLUE stock

What is the GLUE stock price forecast for 2026-2027?

The 9 Wall Street analysts covering Monte Rosa Therapeutics, Inc. have a median 12-month price target of $27, with estimates ranging from $25 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GLUE stock a buy right now?

Of the 9 analysts covering Monte Rosa Therapeutics, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Monte Rosa Therapeutics, Inc. 63 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GLUE?

As at 8 Oct 2026, Monte Rosa Therapeutics, Inc. ranks 63 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (82 of 100).

Will GLUE stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +161.6% from the last close, and Ticker Nerd's factor model ranks Monte Rosa Therapeutics, Inc. 63 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GLUE stock forecast for 2030?

No analyst covering Monte Rosa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $37 over the next 12 months.

How has GLUE stock performed over the past year?

Monte Rosa Therapeutics, Inc. returned +33.9% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Monte Rosa Therapeutics, Inc. do?

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins.

What is the latest news on GLUE?

The most recent item we track (MarketBeat, 6 Oct 2026): "Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 Study". Monte Rosa Therapeutics reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The four-week dosing study showed sustained NEK7 degradation, reductions in inflammatory and atherogenic biomarkers, and a safety profile comparable with placebo.

Company

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins. Its current pipeline includes orally available small-molecule candidates for oncology, autoimmune and inflammatory disorders, and other serious diseases, using the body’s natural protein-degradation machinery to address targets that are difficult to treat with conventional drugs. The company’s research is centered on precision medicine approaches that combine chemistry, structural biology, proteomics, and computational methods to identify and optimize novel therapies. Monte Rosa Therapeutics, Inc. operates in the biotechnology sector, where targeted protein degradation is an important area of drug discovery and development.

CEO Dr. Markus Warmuth M.D. · 173 employees · United States · https://www.monterosatx.com